1. Clinical conditions and risk factors for inhibitor‐development in patients with haemophilia: A decade‐long prospective cohort study in Japan, J‐HIS2 (Japan Hemophilia Inhibitor Study 2). Issue 5 (11th June 2022) Authors: Nogami, Keiji; Taki, Masashi; Matsushita, Tadashi; Kojima, Tetsuhito; Oka, Toshiaki; Ohga, Shouichi; Kawakami, Kiyoshi; Sakai, Michio; Suzuki, Takashi; Higasa, Satoshi; Horikoshi, Yasuo; Shinozawa, Keiko; Tamura, Shogo; Yada, Koji; Imaizumi, Masue; Ohtsuka, Yoshitoshi; Iwasaki, Fuminori; Kobayash... Journal: Haemophilia Issue: Volume 28:Issue 5(2022) Page Start: 745 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Postmarketing safety and effectiveness of recombinant factor IX (nonacog alfa) in Japanese patients with haemophilia B. Issue 4 (6th June 2019) Authors: Fukutake, Katsuyuki; Taki, Masashi; Matsushita, Tadashi; Sakai, Michio; Takata, Ami; Yamaguchi, Hiromi; Karumori, Toshiyuki Journal: Haemophilia Issue: Volume 25:Issue 4(2019) Page Start: e247 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. The prevalence of neutralizing antibodies against adeno‐associated virus capsids is reduced in young Japanese individuals. Issue 11 (17th October 2013) Authors: Mimuro, Jun; Mizukami, Hiroaki; Shima, Midori; Matsushita, Tadashi; Taki, Masashi; Muto, Shinji; Higasa, Satoshi; Sakai, Michio; Ohmori, Tsukasa; Madoiwa, Seiji; Ozawa, Keiya; Sakata, Yoichi Journal: Journal of medical virology Issue: Volume 86:Issue 11(2014:Nov.) Page Start: 1990 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗